IO Biotech, Inc.
IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing therapeutic cancer vaccines, with its lead program IO102-IO103 now referred to in the U.S. as Cylembio® (imsapepimut and etimupepimut, adjuvanted). The company is focused on advancing oncology immunotherapy candidates through clinical trials and regulatory approval, with no approved products or product revenue to date.
Fiscal year 2024 · change from previous year
Development 2020–2024
Business
Share of revenueClinical-stage vaccine program targeting oncology indications, including Cylembio®/IO102-IO103.
Earlier-stage preclinical and discovery assets intended to expand the oncology pipeline.
Internal R&D, trial execution, and regulatory work needed to advance candidates toward approval.
Customers
IO Biotech does not yet sell approved products, so it currently has no commercial customer base. Its future customers would be oncology physicians, hospitals, and treatment centers if Cylembio® or other candidates reach approval, while near-term stakeholders are regulators, clinical investigators, and potential collaborators.
Hospitals, cancer centers, and physicians would buy or administer approved therapies if the pipeline succeeds.
End users of the therapy, especially in indications addressed by IO102-IO103/Cylembio®.
FDA and foreign agencies evaluate the clinical package and determine whether products can be commercialized.
Pharma partners may fund, co-develop, or commercialize programs and provide non-dilutive capital.
Strategy
IO Biotech’s strategy is to advance Cylembio® through late-stage clinical development and generate the data needed for regulatory approval. The company is also focused on preserving liquidity through equity, debt, collaborations, and non-dilutive funding while it remains pre-revenue and capital intensive.
Approval depends on positive late-stage data and successful trial execution.
Current cash is not sufficient to fund all planned development activities.
If approved, the company must build or outsource sales, marketing, and distribution.
Geography
The company is headquartered in the United States, but its operating footprint is international, with references to Denmark and European financing through the EIB loan facility. Its clinical and regulatory work is tied to U.S. and foreign oncology markets, and future commercialization would likely depend on approvals and reimbursement across multiple jurisdictions.
Risks
IO Biotech is a pre-revenue oncology developer with substantial clinical, regulatory, financing, and commercialization risk. Its lead asset may fail in later-stage trials, approval may be delayed or denied, and the company may need more capital before it can reach commercialization or even continue as a going concern.
- Clinical development failureImpact: CriticalLikelihood: High
The lead candidate is still in development and early results may not predict later outcomes.
Exposure: Cylembio® / IO102-IO103
- Going concern and financing riskImpact: CriticalLikelihood: High
The company expects to need additional capital to fund future clinical and preclinical work.
Exposure: All programs and operations
- Commercialization execution riskImpact: HighLikelihood: Medium
The company has no sales, marketing, or distribution infrastructure.
Exposure: Future approved products
- Manufacturing and supply chain riskImpact: HighLikelihood: Medium
Specialty materials and contract manufacturing are needed for clinical and commercial supply.
Exposure: API and product supply
- Competitive and technological obsolescenceImpact: HighLikelihood: Medium
Oncology is crowded and faster or better therapies could reduce market opportunity.
Exposure: Oncology immunotherapy market
Accounting
Judgemental itemsManagement says cash may not fund operations beyond the near term without new capital.
Impact: Affects financial statement presentation and investor assessment of survival risk
Clinical and preclinical spending is expensed as incurred, creating volatile operating losses.
Impact: Drives reported loss and masks underlying progress until commercialization
The company concluded future taxable income is unlikely enough to realize deferred tax assets.
Impact: Prevents tax benefits from reducing reported losses
Bundled share and warrant transactions require relative fair value allocation.
Impact: Can materially affect equity and non-cash expense recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
IN8bio, Inc
INAB · Biological Products, (No Diagnostic Substances)
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
iBio, Inc.
IBIO · Pharmaceutical Preparations
Last updated: 24/09/2026